CLIENT RESULT
Diagnostics

Seven pharmas, two access strategies, one consortium-funded path forward.

Andrew Aijian, PhD

Partner
View Profile
capabilities
Investment Diligence
Project Details
capability
Investment Diligence

Objective

Seven of the world's largest pharmaceutical companies needed a near-term action plan to expand liquid biopsy access globally. Andrew's team produced two region-specific roadmaps, and the consortium has continued to execute on the work publicly, most recently at ASCO 2025.
Key Metrics
46
Stakeholder Interviews
6
Markets Profiled
5
Barrier Archetypes Assessed Per Market

Our Approach

Andrew Aijian led the engagement. As author of DeciBio’s Liquid Biopsy Market Report and a longtime advisor to precision-medicine players across pharma, Dx, and reference labs, he brought the domain fluency the consortium needed to evaluate solutions a generalist team would have struggled to weigh. The work ran in two phases bridged by an in-person workshop at ASCO.

Phase 1 mapped the access landscape, with a focus on understanding key barriers and their severity. The team interviewed 37 oncologists, molecular pathologists, lab directors, and policy and payor experts across the U.S., UK, Germany, France, Italy, and Spain to characterize how liquid biopsy was actually being ordered, performed, and reimbursed in each market, and where it wasn’t. Secondary research catalogued the precision-medicine initiatives already implemented globally, so the consortium could see where it could amplify existing efforts versus where it needed to fill gaps itself. The output was a market-by-market view of which barriers were present and actionable, and which were proxies for deeper structural problems.

At an ASCO workshop, candidate solutions were brainstormed and pressure tested amongst the PCC and DeciBio working teams as well as an advisory panel of oncologists whose perspectives were hand-selected to reflect the institutional and regional diversity emphasized in the research findings. The engagement ultimately converged on a shortlist of interventions worth validating in the next phase of research.

Phase 2 stress-tested the shortlist against a fresh slate of nine clinician KOLs across both regions. Each candidate was evaluated for impact, feasibility, and sustainability, separately for the U.S. and Europe, because the answer differed by region. For the highest-priority intervention, the team also evaluated three structural models for how it could be implemented, since the model choice (integrate into an existing accreditation framework, partner with an established body, or build new) determined which partner organizations PCC could plausibly engage.

Outcome

PCC left the engagement with two distinct, region-specific roadmaps: one for the U.S. focused on closing access gaps in underserved communities, one for Europe focused on building infrastructure ahead of reimbursement. Each named the partner archetypes worth approaching, the investment shape required, and the metrics by which the consortium could measure whether the program was working. PCC publicly described the engagement as producing “insights into the adoption of liquid biopsy testing and find solutions for under-served populations,” and has continued to maintain liquid biopsy access and adoption as one of its two flagship workstreams, most visibly at ASCO 2025, where the consortium reconvened a Scientific Steering Committee around the project a year after the readout. In March 2026, PCC signed a four-year agreement with the Galician regional health service (SERGAS) to make comprehensive genomic profiling a systemic tool in routine cancer care, with Spain serving as the European pilot, directionally consistent with the engagement’s recommendation that Europe’s path forward ran through partnerships with established health-system authorities rather than direct community access.

Project Details
Geographic Scope
U.S. and EU-4 + UK
Precision Medicine is evolving at a rapid pace

Discover how we can help

Get in Touch